SBRT compared to sorafenib in locally advanced hepatocellular carcinoma: a propensity score analysis

被引：0

作者：

Gkika, E. ^{[1
]}

Brunner, T. ^{[2
]}

Abbasi-Senger, N. ^{[3
]}

Alheit, H.

Baus, W. ^{[4
]}

Blanck, O. ^{[5
]}

Gerum, S. ^{[6
]}

Guckenberger, M. ^{[7
]}

Habermehl, D. ^{[8
]}

Ostheimer, C. ^{[9
]}

Riesterer, O. ^{[7
]}

Tamihardja, J. ^{[10
]}

Pinato, D. J. ^{[11
]}

Rimassa, L. ^{[12
]}

Pressiani, T. ^{[12
]}

Schultheiss, M. ^{[13
]}

Sharma, R. ^{[11
]}

Burlone, M. E. ^{[14
]}

Pirisi, M. ^{[14
]}

Kudo, M. ^{[15
]}

Park, J. W. ^{[16
]}

Neumann-Haefelin, C. ^{[17
]}

Grosu, A. ^{[18
]}

Thimme, R. ^{[17
]}

Bettinger, D. ^{[17
]}

机构：

[1] Uniklin Freiburg, Radiat Oncol, Freiburg, Germany

[2] Univ Magdeburg, Radiat Oncol, Magdeburg, Germany

[3] Univ Jena, Radiat Oncol, Jena, Germany

[4] Univ Hosp Cologne, Radiat Oncol, Cologne, Germany

[5] Univ Med Ctr Schleswig Holstein, Dept Radiat Oncol, Campus Kiel, Kiel, Germany

[6] Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, Munich, Germany

[7] Univ Hosp Zurich, Dept Radiat Oncol, Zurich, Switzerland

[8] Tech Univ Munich, Dept Radiat Oncol, Klinikum Rechts Isar, Munich, Germany

[9] Martin Luther Univ Halle Wittenberg, Dept Radiat Oncol, Halle, Germany

[10] Univ Hosp Wurzburg, Dept Radiat Oncol, Wurzburg, Germany

[11] Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp, London, England

[12] Humanitas Canc Ctr, Humanitas Clin & Res Ctr, Med Oncol & Hematol Unit, Milan, Italy

[13] Univ Freiburg, Med Ctr, Dept Med 2, Freiburg, Germany

[14] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

[15] Kindai Univ, Sch Med, Dept Gastroenterol & Hepatol, Osakasayama, Japan

[16] Natl Canc Ctr Hosp, Ctr Liver Canc, Goyang, South Korea

[17] Univ Freiburg, Med Ctr, Dept Med 2, Freiburg, Germany

[18] Univ Freiburg, Dept Radiat Oncol, Med Ctr, Freiburg, Germany

来源：

RADIOTHERAPY AND ONCOLOGY | 2019年 / 133卷

关键词：

D O I：

10.1016/S0167-8140(19)31231-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO-0811

引用

页码：S423 / S423

页数：1

共 50 条

[31] How to guide sorafenib for advanced hepatocellular carcinoma? Usefulness of NIACE score
Adhoute, Xavier
Penaranda, Guillaume
Raoul, Jean Luc
Blanc, Jean Frederic
Edeline, Julien
Conroy, Guillaume
Perrier, Herve
Castellani, Paul
Pol, Bernard
Bronowicki, Jean Pierre
Bourliere, Marc
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 340 - 340
[32] Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Kan, Xuefeng
Liang, Bin
Zhou, Guofeng
Xiong, Bin
Pan, Feng
Ren, Yanqiao
Cao, Yanyan
Wang, Jihua
Yang, Fan
Zheng, Chuansheng
FRONTIERS IN ONCOLOGY, 2020, 10
[33] Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (vol 11, 737767, 2021)
Kuo, Yuan-Hung
Lu, Sheng-Nan
Chen, Yen-Yang
Kee, Kwong-Ming
Yen, Yi-Hao
Hung, Chao-Hung
Hu, Tsung-Hui
Chen, Chien-Hung
Wang, Jing-Houng
FRONTIERS IN ONCOLOGY, 2021, 11
[34] Additive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced-Stage Hepatocellular Carcinoma: Propensity analysis
Choi, Gwang Hyeon
Shim, Ju Hyun
Lee, Danbi
Kim, Kang Mo
Lim, Young-Suk
Lee, Han Chu
Chung, Young-Hwa
Lee, Yung Sang
Suh, Dong Jin
Kang, Yoon-Koo
HEPATOLOGY, 2012, 56 : 469A - 469A
[35] Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis
Chen, Jinbin
Lu, Shixun
Zhang, Yaojun
Xu, Li
Chen, Jiancong
Wang, Juncheng
Chen, Minshan
Zhang, Rongxin
Zhou, Zhongguo
JOURNAL OF CANCER, 2018, 9 (10): : 1745 - 1753
[36] Hepatocellular Carcinoma: Concomitant Sorafenib Promotes Necrosis after Radiofrequency Ablation-Propensity Score Matching Analysis
Fukuda, Hiroyuki
Numata, Kazushi
Moriya, Satoshi
Shimoyama, Yu
Ishii, Tomohiro
Nozaki, Akito
Kondo, Masaaki
Morimoto, Manabu
Maeda, Shin
Sakamaki, Kentaro
Morita, Satoshi
Tanaka, Katsuaki
RADIOLOGY, 2014, 272 (02) : 598 - 604
[37] Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis (vol 8, pg 281, 2019)
Bettinger, D.
Pinato, D. J.
Schultheiss, M.
LIVER CANCER, 2019, 8 (04) : 295 - 295
[38] REGORAFENIB VERSUS NIVOLUMAB FOR HEPATOCELLULAR CARCINOMA PATIENTS WHO EXPERIENCED SORAFENIB TREATMENT FAILURE: A PROPENSITY SCORE ANALYSIS
Lee, Cheol-Hyung
Lee, Yun Bin
Kim, Minseok Albert
Jang, Heejoon
Kim, Sun Woong
Cho, Eun Ju
Lee, Jeong-Hoon
Yu, Su Jong
Yoon, Jung-Hwan
Kim, Yoon Jun
HEPATOLOGY, 2019, 70 : 212A - 213A
[39] Donafenib versus sorafenib in triple therapy for unresectable hepatocellular carcinoma: a propensity score-matched multicenter analysis
Yaohong Wen
Shuyi Zhou
Yuyan Xu
Cheng Zhang
Zhoubin Feng
Yinghui Song
Bai Ding
Chuang Peng
Hongkun Tan
Chunming Wang
Jianan Feng
Jingyuan Pei
Guolin He
Shunjun Fu
Lvhuan Wang
Lei Cai
Sulai Liu
Mingxin Pan
World Journal of Surgical Oncology, 23 (1)
[40] Complete Regression of Locally Advanced Hepatocellular Carcinoma (HCC) Following Sorafenib Monotherapy
Kumar, Shiva
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S374 - S374

← 1 2 3 4 5 →